Ton Berkien has been elected Chairman of the Board of Directors of Gedea Biotech.
He replaces Olov Sterner, one of the founders of Gedea who continues as a board member. The appointment further strengthens the Board of Directors business development expertise, with Berkien bringing 20 years of experience in business development, and M&A, states Gedea.
“Ton Berkien has extensive experience and expertise in business development. The recruitment of Ton will further strengthen the board and the company as we prepare for our planned upcoming partnering work with pHyph,” says Annette Säfholm, CEO of Gedea.
Ton Berkien holds a bachelor’s degree in economics from Saxion University in the Netherlands and life science industry Diploma from PwC/Harvard Business School/IMD. Since starting as head of competitive intelligence at Ferring Pharmaceuticals in 2003, he has held a number of senior positions in leading life science companies including Nycomed/Takeda, Neuvolution and Amgen, primarily in business development. Currently he serves as Chief Business Offices for Norwegian biotech Ultimovacs. Ton has both Swedish and Dutch citizenship and lives in Sweden together with his family.
“I am pleased that the owners have placed their confidence in me as chairman of Gedea and I am excited about the task,” says Ton Berkien. “Gedea is a company with great potential and I look forward to working actively with the partnering process.”
Photo of Ton Berkien: Gedea